HUM

In late 2025 and early 2026, Humana's stock was impacted by Medicare Advantage margin concerns due to higher utilization and reimbursement pressure, leading to a net loss per share in Q4 2025 and an anticipated FY 2026 GAAP EPS decline from Star Ratings headwinds. In Q1 CY2026 (April 2026), Humana met Wall Street's revenue expectations with 23.5% year-on-year growth to $39.65 billion but missed GAAP profit per share estimates by 8.6%. In October 2026, Humana's stock soared by over 15% following the announcement of a significant improvement in its Medicare Advantage star ratings for 2027, with 95% of its members now in plans rated four stars or higher, up from 20% a year prior. This achievement is expected to qualify Humana for over $3 billion in bonus payments in 2028, and its largest MA contract improved from 3.5 to 4 stars. Overall, the stock price increased by 31.56% between October 6, 2025, and October 2, 2026.